NASDAQ$MRSN

Mersana Therapeutics Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Mersana reported financial results and business update for Q4 2022.

Mersana Therapeutics reported their Q4 and Full Year 2022 financial results, highlighting advancements in their lead product candidate UpRi, diversification of their clinical pipeline, new collaborations, and a strengthened financial position.

  • Advanced UpRi in multiple clinical trials.
  • Diversified clinical pipeline.
  • Entered significant new collaborations.
  • Strengthened financial position.

Headline financials

Total Revenue

$14.7M

Previous: $11K+133427.3%
EPS (adj)

-$0.44

Previous: -$0.68+35.3%
Capital Expenditures

$785K

Previous: $155K+406.5%
Free Cash Flow

-$52M

Previous: -$42.6M-22.2%
Net Income

$0.00

Previous: -$49M+100.0%
Operating Income

$0.00

No prior period
Gross Profit

$14.4M

Previous: -$37.4M+138.6%
Cash & Equivalents

$0.00

Previous: $178M-100.0%
Total Assets

$0.00

Previous: $206M-100.0%
Stock-Based Comp

$5.31M

Previous: $4.86M+9.3%

Revenue & EPS history

Mersana · Revenue · Quarterly

$14.7M

Q4 2022+133,427.3%vs Q4 2021
Beat estimate in 6 of 16 quarters(38%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+1.4%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+1.3%

Avg return

30 days after

47%

17 / 36 earnings

Positive

+38.9%

Q2 2022

Best reaction

-20.3%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025+2.4%+0.8%+3.0%
Q2 2025+11.6%+22.3%+18.6%
Q1 2025-18.5%-0.2%-3.6%
Q4 2024-8.3%+3.6%-36.7%
Q3 2024+14.5%-3.7%-1.8%
Q2 2024-13.4%-7.2%+25.2%
Q1 2024-20.3%-23.8%-37.4%
Q4 2023+27.4%+33.8%+4.8%
Q3 2023-6.5%-12.9%+46.8%
Q2 2023+0.0%+4.2%+6.7%
Q1 2023+8.9%+8.2%+16.4%
Q4 2022+7.0%+4.4%-26.3%
Q3 2022-11.0%
Q2 2022+38.9%
Q1 2022-11.2%
Q4 2021+14.4%
Q3 2021-1.1%
Q2 2021-2.1%
Q1 2021-5.3%
Q4 2020+7.7%
Q3 2020-4.2%
Q2 2020-1.9%
Q1 2020-3.1%
Q4 2019+3.5%
Q3 2019+7.0%
Q2 2019+2.3%
Q1 2019+14.3%
Q4 2018+4.0%
Q3 2018+7.5%
Q2 2018+0.0%
Q1 2018-3.7%
Q1 2016-8.9%
Q3 2016-4.5%
Q3 2017-5.1%
Q4 2016+3.9%
Q2 2016+3.9%
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro